REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 149 filers reported holding REATA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $16,609,794 | -24.8% | 162,905 | -33.0% | 0.00% | 0.0% |
Q1 2023 | $22,099,106 | -20.7% | 243,061 | -66.9% | 0.00% | -33.3% |
Q4 2022 | $27,874,480 | +254.1% | 733,732 | +134.2% | 0.00% | +200.0% |
Q3 2022 | $7,873,000 | -2.7% | 313,242 | +17.7% | 0.00% | 0.0% |
Q2 2022 | $8,091,000 | -19.4% | 266,212 | -13.1% | 0.00% | 0.0% |
Q1 2022 | $10,038,000 | +45.0% | 306,401 | +16.7% | 0.00% | 0.0% |
Q4 2021 | $6,924,000 | -58.2% | 262,597 | +59.7% | 0.00% | -50.0% |
Q3 2021 | $16,548,000 | +70.5% | 164,475 | +139.8% | 0.00% | +100.0% |
Q2 2021 | $9,706,000 | +56.0% | 68,580 | +9.9% | 0.00% | 0.0% |
Q1 2021 | $6,220,000 | +36.6% | 62,387 | +69.3% | 0.00% | 0.0% |
Q4 2020 | $4,554,000 | +34.2% | 36,848 | +5.8% | 0.00% | 0.0% |
Q3 2020 | $3,393,000 | -75.9% | 34,827 | -61.4% | 0.00% | -66.7% |
Q2 2020 | $14,086,000 | -15.0% | 90,293 | -21.4% | 0.00% | -40.0% |
Q1 2020 | $16,579,000 | +46.7% | 114,864 | +107.7% | 0.01% | +66.7% |
Q4 2019 | $11,305,000 | +407.0% | 55,301 | +99.1% | 0.00% | +200.0% |
Q3 2019 | $2,230,000 | +9.6% | 27,777 | +28.8% | 0.00% | 0.0% |
Q2 2019 | $2,034,000 | -27.3% | 21,559 | -34.1% | 0.00% | 0.0% |
Q1 2019 | $2,796,000 | -3.9% | 32,707 | -37.0% | 0.00% | 0.0% |
Q4 2018 | $2,910,000 | -36.0% | 51,878 | -6.8% | 0.00% | 0.0% |
Q3 2018 | $4,549,000 | +143.9% | 55,641 | +4.3% | 0.00% | 0.0% |
Q2 2018 | $1,865,000 | +89.9% | 53,350 | +11.5% | 0.00% | – |
Q1 2018 | $982,000 | -1.0% | 47,846 | +36.7% | 0.00% | – |
Q4 2017 | $992,000 | +14.3% | 35,011 | +25.4% | 0.00% | – |
Q3 2017 | $868,000 | +43.9% | 27,912 | +46.4% | 0.00% | – |
Q2 2017 | $603,000 | -22.7% | 19,064 | -44.6% | 0.00% | – |
Q1 2017 | $780,000 | -31.3% | 34,404 | -34.0% | 0.00% | – |
Q4 2016 | $1,136,000 | +176.4% | 52,116 | +233.9% | 0.00% | – |
Q3 2016 | $411,000 | +195.7% | 15,610 | +121.6% | 0.00% | – |
Q2 2016 | $139,000 | – | 7,043 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |